Edgewise Therapeutics (EWTX)

• Market cap: $2.49B
• 1 day: -1.72%
• 5 days: 12.13%
• 1 month: -12.96%
• 3 months: -26.05%
• 6 months: 22.20%
• Year to date: -2.85%
• 1 year: 161.55%
• 5 years: -12.47%
• 10 years: -12.47%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Employees: 108

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

349% more call options, than puts

Call options by funds: $60M | Put options by funds: $13.3M

240% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 15

48% more capital invested

Capital invested by funds: $1.84B [Q2] → $2.71B (+$873M) [Q3]

33% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 8 (+2) [Q3]

25% more funds holding

Funds holding: 140 [Q2] → 175 (+35) [Q3]

22% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 46

0.89% less ownership

Funds ownership: 109.17% [Q2] → 108.27% (-0.89%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 71% upside
• Avg. target: $48 84% upside
• High target: $50 90% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Evercore ISI Group Cory Kasimov 40% 1-year accuracy 6 / 15 met price target	90% upside $50	Outperform Maintained	17 Dec 2024
Truist Securities Srikripa Devarakonda 30% 1-year accuracy 10 / 33 met price target	90% upside $50	Buy Maintained	27 Nov 2024
Wedbush Laura Chico 25% 1-year accuracy 15 / 61 met price target	71% upside $45	Outperform Maintained	8 Nov 2024